Demographic and Clinical Characteristics of Patients with Severe Asthma who Continued, Stopped or Switched Biologic Therapy

Andrew Menzies-Gow, Eileen Wang, Bindhu Unni, Marianna Alacqua, Mona Al-Ahmad, John Busby, Lakmini Bulathsinhala, Victoria Carter, Isha Chaudry, Tuck Seng Cheng, Borja G. Cosio, Neva Eleangovan, J. Mark FitzGerald, Liam G. Heaney, Mark Hew, Naeimeh Hosseini, David Jackson, Maria Kallieri, Désirée Larenas-Linnemann, Stelios LoukidesNjira Lugogo, Ruth Murray, Andriana I. Papaioannou, Luis Perez-de-Llano, Celeste Porsbjerg, Linda M. Rasmussen, Salman Siddiqui, Johannes Schmid, Trung N. Tran, Charlotte Ulrik, John W Upham, David Price

Research output: Contribution to conferenceAbstractpeer-review

Abstract

INTRODUCTION: Biologics, which are monoclonal antibodies targeting molecular intermediates, provide a promising therapy for severe asthmatics. Thus, biologics have quickly become integrated into the treatment regimen of severe asthma. However, there is limited knowledge of the pattern of use of biologic therapy in current clinical practice (i.e. continue, stop, switch) and the characteristics underpinning these patterns. This study thus aimed to explore baseline clinical and demographic characteristics of a real-life severe asthma cohort according to pattern of biologic use.
Original languageEnglish
Publication statusAccepted/In press - 19 Mar 2020
EventRespiratory Effectiveness Group Summit 2020 -
Duration: 19 Mar 202021 Mar 2020

Conference

ConferenceRespiratory Effectiveness Group Summit 2020
Period19/03/2021/03/20

Fingerprint

Dive into the research topics of 'Demographic and Clinical Characteristics of Patients with Severe Asthma who Continued, Stopped or Switched Biologic Therapy'. Together they form a unique fingerprint.

Cite this